Global incidence and prevalence of hypertension continues to increase and remains a significant challenge. The ever-increasing number of cases are due to comorbid conditions such as obesity and diabetes, as well as lifestyle indiscretions such as excessive salt intake. Hypertension, congestive heart failure, and kidney disease are all conditions resulting from abnormal Renin-Angiotensin-Aldosterone activation and adverse remodeling. Firibastat, a novel Brain Aminopeptidase inhibitor, may be able to help achieve blood pressure control in those with resistant hypertension. In this review article, we will discuss the biochemical pathway of firibastat and various trials assessing drug efficacy in animals and humans. This drug has the potential to curb the risk of uncontrolled hypertension and help improve long term cardiovascular morbidity and mortality.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cpcardiol.2021.100859 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
New Approaches Targeting the Renin-Angiotensin System: Inhibition of Brain Aminopeptidase A, ACE2 Ubiquitination, and Angiotensinogen.
Can J Cardiol
December 2023
Division of Pharmacology, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands. Electronic address:
Despite the availability of various therapeutic classes of antihypertensive drugs, hypertension remains poorly controlled, in part because of poor adherence. Hence, there is a need for the development of antihypertensive drugs acting on new targets to improve control of blood pressure. This review discusses novel insights (including the data of recent clinical trials) with regard to interference with the renin-angiotensin system, focusing on the enzymes aminopeptidase A and angiotensin-converting enzyme 2 (ACE2) in the brain, as well as the substrate of renin- angiotensinogen-in the liver.
View Article and Find Full Text PDFNew and developing pharmacotherapies for hypertension.
Expert Rev Cardiovasc Ther
August 2022
Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) - Universidad de Buenos Aires, Instituto Alberto C. Taquini de Investigaciones en Medicina Traslacional (IATIMET), Buenos Aires, Argentinae.
Article Synopsis
- - Despite the global impact of hypertension, treatment remains inadequate, leading to the development of new antihypertensive medications with unique action mechanisms.
- - This review highlights recent advancements in drug development, emphasizing innovations in drug formulations and the potential of modifying intestinal microbiota for better blood pressure management.
- - New agents like sacubitril/valsartan and SGLT2 inhibitors show promise as first-line treatments, while strategies involving prebiotics and probiotics may help in preventing hypertension and improving blood pressure control.
Firibastat: a Novel Treatment for Hypertension.
Curr Hypertens Rep
December 2021
University of Texas Southwestern, 5323 Harry Hines Blvd S2.210, Dallas, TX, 75390-9006, USA.
Article Synopsis
- The review highlights firibastat as a new medication for treating hypertension, focusing on its unique mechanism targeting the brain's renin angiotensin system.
- Recent clinical trials indicate that firibastat is effective and safe for both mild and resistant hypertension, making it a promising option for patients with difficult-to-treat cases.
- Firibastat represents a new therapeutic class in hypertension treatment, showing significant blood pressure reduction with minimal side effects.
Firibastat: A Novel Brain Aminopeptidase Inhibitor - A New Era of Antihypertensive therapy.
Curr Probl Cardiol
September 2022
Lehigh Valley Heart Institute, Lehigh Valley Health Network, Allentown, PA.
Global incidence and prevalence of hypertension continues to increase and remains a significant challenge. The ever-increasing number of cases are due to comorbid conditions such as obesity and diabetes, as well as lifestyle indiscretions such as excessive salt intake. Hypertension, congestive heart failure, and kidney disease are all conditions resulting from abnormal Renin-Angiotensin-Aldosterone activation and adverse remodeling.
View Article and Find Full Text PDFFiribastat, the first-in-class brain aminopeptidase a inhibitor, in the management of hypertension: A review of clinical trials.
Avicenna J Med
January 2021
College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
An unfortunate subset of hypertensive patients develops resistant hypertension in which optimal doses of three or more first-line antihypertensive drugs fail to sufficiently control blood pressure. Patients with resistant hypertension represent a high-risk and difficult-to-treat group, and such patients are at amplified jeopardies for substantial hypertension-related multi-organ failure, morbidity, and mortality. Thus, there is a pressing requirement to better improve blood pressure control through the pharmaceutical generation of novel classes of antihypertensive drugs that act on newer and alternative therapeutic targets.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!